Mpex Pharmaceuticals mpexpharma.com


Public lists: Pharma Startups (4732)

Mpex Pharmaceuticals is a biopharmaceutical company developing an inhaled antibiotic for the treatment of cystic fibrosis and chronic obstructive pulmonary disease and therapies to combat the growing issue of antibiotic resistance. Mpex's lead product is a proprietary aerosol formulation of the antibiotic levofloxacin in Phase III trials for the treatment of pulmonary infections in patients with cystic fibrosis. In April 2011, Axcan Pharma acquired all assets related to Aeroquin. Axcan sp...Show all

Mpex Pharmaceuticals is a biopharmaceutical company developing an inhaled antibiotic for the treatment of cystic fibrosis and chronic obstructive pulmonary disease and therapies to combat the growing issue of antibiotic resistance. Mpex's lead prod...Show all

Company (Acquired)

Phone: 858-875-2840

Fax:

11535 Sorrento Valley Road

San Diego, 92121
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Mpex Pharmaceuticals $73M Apr 16, 2011
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Mpex Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 10 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Esperion Therapeutics

Ann Arbor, Michigan, United States
IPO / Went publicEsperion Therapeutics discovers and develops therapies for the treatment of cardiometabolic diseases. The company's lead product candidate, ETC-1002, is an AMP kinase activator and ATP citrate lyase inhibitor that is being evaluated in multiple Phase 2 clinical trials for the treatment of hypercholesterolemia and other cardiometabolic risk factors. Esperion intends to commercialize first-in-class therapies focused on enhancing lipid regulation, addressing statin intolerance and improving overall...Show allLogin to see details

Ocera Therapeutics

Redwood City, California, United States
AcquiredOcera Therapeutics is focused on the development and commercialization of therapeutics for gastrointestinal and liver diseases. The company's portfolio consists of OCR-002 and AST-120. OCR-002 is an ammonia scavenger in development for the treatment and prevention of hyperammonemia and resultant Acute Hepatic Encephalopathy (AHE) in patients with liver cirrhosis and Acute Liver Failure (ALF). OCR-002 is developed in both oral and IV formulations. AST-120 is a microspherical carbon adsorbent with...Show allLogin to see details
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Topical use of levofloxacin for reducing lung inflammation Oct 06, 2009 Jan 14, 2014 Patent
Aerosolized fluoroquinolones and uses thereof Oct 22, 2009 Oct 01, 2013 Patent
Aerosolized fluoroquinolones and uses thereof Oct 22, 2009 Sep 03, 2013 Patent
Aerosolized fluoroquinolones and uses thereof Oct 22, 2009 Sep 03, 2013 Patent
Aerosolized fluoroquinolones and uses thereof Jan 28, 2010 Jan 22, 2013 Patent
See all 11 patents